In recent years, drugs for psoriasis have been screened as target suppression of IL-17A, IL-23, and Janus kinase (JAK), such as ustekinumab, ixekizumab, and tofacitinib, which are well effective but expensive (9–13). Here, IL17A is linked to psoriasis.